Cervical Cancer Epidemiology Analysis and Forecast, 2020-2030

Pages: 42 Published: January 31, 2022 Report Code: GDHCER292-22

There were 109,891 cases of diagnosed incident cases of cervical cancer in the 8MM in 2020. The number of diagnosed incident cases is expected to increase further at an annual growth rate (AGR) of more than 1% during the forecast period. In 2030, urban China is expected to have the highest number of diagnosed incident cases of cervical cancer. The report cervical cancer epidemiology report provides an overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China).

The cervical cancer epidemiology report provides an overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It includes a 10-year epidemiological forecast for diagnosed incident cases of cervical cancer. The diagnosed incident cases of cervical cancer are further segmented by age (18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, 70–79 years, and 80 years and older) in these markets. Diagnosed incident cases of cervical cancer are further segmented by International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis (stage IA, stage IB1-2, stage IB3, stage IIA1, stage IIA2, stage IIB, stage III, stage IVA, and stage IVB), histology subtypes (squamous cell carcinoma, adenocarcinoma, adenosquamous carcinomas, small cell neuroendocrine cancers, and others), biomarkers (MSI, MMR-d, PD-L1 positive, NTRK fusion, and HER2), and HPV status (HPV 16, HPV 18, HPV 31, HPV 33, HPV 45, HPV 52, and HPV 58). The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of cervical cancer.

Overview of cervical cancer epidemiology

Overview of cervical cancer epidemiology

For more insights on this report, download a free report sample

What are the market dynamics of cervical cancer epidemiology?

Identifying risk factors like age, HPV, sexual history, smoking, immune system deficiency, oral contraceptives, exposure to diethylstilbestrol, and sexually transmitted infections (STIs) is essential for the prevention and treatment of cervical cancer. Additionally, cervical cancer survivors reported a higher prevalence of comorbidities such as heart disease, liver disease, hypertension, gastrointestinal disease, and musculoskeletal disease.

In 2020, the diagnosed incidence of cervical cancer was highest in urban China, followed by Japan and Germany, and was lowest in the US. The rate of increase was highest in urban China. There is no HPV vaccination program there because of the high prices of imported vaccines, and the coverage of cervical cancer screening remains low. HPV vaccination in Japan began in 2010 for girls ages 12–16 years, with three-dose coverage initially reaching more than 70% of the population. In 2013, two months after a formal inclusion in Japan’s national immunization program, proactive recommendations for the HPV vaccine were suspended following reports of adverse events that have since been found to be unrelated to vaccination. Vaccine coverage subsequently dropped to less than 1% and has remained this low to date.

What are the major segments in cervical cancer epidemiology?

The major segments for cervical cancer epidemiology are the International Federation of Gynecology and Obstetrics stage at diagnosis, histology, biomarker, and human papillomavirus status.

FIGO stage at diagnosis of cervical cancer epidemiology

In the 8 major markets, the highest number of diagnosed incident cases of cervical cancer was in stages IB1-2, followed by stage IA, and stage IIB. Among the 8MM, urban China had the highest number of diagnosed incident cases of cervical cancer in stage IB1-2, followed by Japan and the US.

Histology of cervical cancer epidemiology

The highest diagnosed incident cases of cervical cancer were in squamous cell carcinoma, followed by adenocarcinoma, adenosquamous carcinomas, and small cell neuroendocrine cancers.

Biomarker of cervical cancer epidemiology

In the 8MM, urban China had the highest number of diagnosed incident cases of cervical cancer that were PD-L1 positive, followed by the US and Japan.

Human papillomavirus status of cervical cancer epidemiology

HPV 16 is the most significant type of HPV status, followed by HPV 18. In the 8MM, urban China had the highest number of diagnosed incident cases of cervical cancer that were HPV 16, followed by the US and Japan.

Cervical cancer epidemiology, by segments

Cervical cancer epidemiology, by segments

For more segment insights, download a free report sample

Market report scope

Diagnosed incident cases (2020) 109,891
Growth rate AGR of >1%
Forecast period 2021-2030
Base year for estimation 2020
Segmentation by type International Federation of Gynecology and Obstetrics Stage at Diagnosis, Histology, Biomarker, and Human Papillomavirus Status

This report provides:

  • An overview of the risk factors, comorbidities, and global and historical trends for cervical cancer in the eight major markets (8MM)
  • A 10-year epidemiological forecast for diagnosed incident cases of cervical cancer. The diagnosed incident cases of cervical cancer are further segmented by age in these markets. Diagnosed incident cases of cervical cancer are further segmented by the International Federation of Gynecology and Obstetrics (FIGO) stage at diagnosis, histology subtypes, biomarkers, and HPV status. The report also provides a 10-year epidemiological forecast of the five-year diagnosed prevalent cases of cervical cancer.
  • Expert analysis of disease trends in the 8MM.
  • An easy-to-navigate, interactive epidemiology model which is transparent with consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to Buy

  • Develop business strategies by understanding the trends shaping and driving the global cervical cancer market.
  • Quantify patient populations in the global cervical cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for cervical cancer therapeutics in each of the markets covered.
  • Understand magnitude of cervical cancer by FIGO stage at diagnosis, histology subtypes, biomarkers (MSI, MMR-d, PD-L1 positive, NTRK Fusion, and HER2), and HPV status.

Table of Contents

| Contents

| List of Tables

| List of Figures

| About GlobalData

1 Cervical Cancer: Executive Summary

1.1 Related Reports

1.2 Upcoming Reports

2 Epidemiology

2.1 Disease Background

2.2 Risk Factors and Comorbidities

2.3 Global and Historical Trends

2.4 8MM Forecast Methodology

2.4.1 Sources

2.4.2 Forecast Assumptions and Methods

2.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of Cervical Cancer (ICD-10 = C53)

2.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of Cervical Cancer by International Federation of Gynecology and Obstetrics Stage at Diagnosis

2.4.5 Forecast Assumptions and Methods: Diagnosed Incident Cases of Cervical Cancer by Histology Subtypes

2.4.6 Forecast Assumptions and Methods: Diagnosed Incident Cases of Cervical Cancer by Biomarkers

2.4.7 Forecast Assumptions and Methods: Diagnosed Incident Cases of Cervical Cancer by Human Papillomavirus Status

2.4.8 Forecast Assumptions and Methods: Five-Year Diagnosed Prevalent Cases of Cervical Cancer

2.5 Epidemiological Forecast for Cervical Cancer (2020–2030)

2.5.1 Diagnosed Incident Cases of Cervical Cancer

2.5.2 Age-Specific Diagnosed Incident Cases of Cervical Cancer

2.5.3 Diagnosed Incident Cases of Cervical Cancer by International Federation of Gynecology and Obstetrics Stage at Diagnosis

2.5.4 Diagnosed Incident Cases of Cervical Cancer by Histology Subtypes

2.5.5 Diagnosed Incident Cases of Cervical Cancer by Biomarkers

2.5.6 Diagnosed Incident Cases of Cervical Cancer by Human Papillomavirus Status

2.5.7 Five-Year Diagnosed Prevalent Cases of Cervical Cancer

2.6 Discussion

2.6.1 Epidemiological Forecast Insight

2.6.2 COVID-19 Impact

2.6.3 Limitations of the Analysis

2.6.4 Strengths of the Analysis

3 Appendix

3.1 Bibliography

3.2 About the Authors

3.2.1 Epidemiologist

3.2.2 Reviewers

3.2.3 Global Director of Therapy Analysis and Epidemiology

3.2.4 Global Head and EVP of Healthcare Operations and Strategy

| Contact Us

List of Tables

Table 1: Risk Factors and Comorbid Conditions Associated with Cervical Cancer

Table 2: 8MM, Diagnosed Incident Cases of Cervical Cancer by FIGO Stage at Diagnosis, Women, Ages ≥18 Years, N, 2020

Table 3: 8MM, Diagnosed Incident Cases of Cervical Cancer by HPV Status, Women, Ages ≥18 Years, N, 2020

List of Figures

Figure 1: 8MM, Diagnosed Incident Cases of Cervical Cancer, Women, N, Ages ≥18 Years, 2020 and 2030

Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Cervical Cancer, Women, N, Ages ≥18 Years, 2020 and 2030

Figure 3: 8MM, Diagnosed Incidence of Cervical Cancer (Cases per 100,000 population), Women, Ages ≥18 Years, 2010–2030

Figure 4: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of Cervical Cancer

Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Cervical Cancer by FIGO Stage at Diagnosis

Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Cervical Cancer by Histology Subtypes

Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Cervical Cancer by Biomarkers and HPV Status

Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Cervical Cancer

Figure 9: 8MM, Diagnosed Incident Cases of Cervical Cancer, N, Women, Ages ≥18 Years, 2020

Figure 10: 8MM, Diagnosed Incident Cases of Cervical Cancer by Age, N, Women, 2020

Figure 11: 8MM, Diagnosed Incident Cases of Cervical Cancer by Histology Subtypes, N, Women, Ages ≥18 Years, 2020

Figure 12: 8MM, Diagnosed Incident Cases of Cervical Cancer by Biomarkers, N, Women, Ages ≥18 Years, 2020

Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Cervical Cancer, N, Women, Ages ≥18 Years, 2020

Frequently Asked Questions

Request a Free Sample
$3995

Can be used by individual purchaser only

$11985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.